PEPCID AC (famotidine) by Johnson & Johnson is histamine h2 receptor antagonists [moa]. First approved in 1999.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
PEPCID AC (famotidine) is an oral H2-receptor antagonist approved in 1999 for treating acid reflux, heartburn, and peptic ulcer disease. It works by reducing gastric acid secretion, providing symptomatic relief in patients with gastroesophageal reflux and related conditions. This is a mature, widely-available over-the-counter medication.
As LOE approaches, the PEPCID AC team is likely transitioning focus toward lifecycle extension, generic management, and maintenance of market position against competitive H2-blockers.
Histamine H2 Receptor Antagonists
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat
A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants
A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.
Worked on PEPCID AC at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on PEPCID AC offers experience in mature brand management, OTC strategy, and generic competition mitigation within a stable but declining revenue environment. Career growth is constrained by LOE and market saturation; roles focus on optimization, cost control, and consumer engagement rather than innovation or expansion.